This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
Over the past two years, two Alzheimer’s disease drugs were approved under accelerated approval. Both drugs are based on popular amyloid beta-plaque theories, yet both have raised questions.
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb), a new monoclonal antibody that seems to slow cognitive decline in some Alzheimer’s patients. In June 2021, Aduhelm (aducanumab) was approved.
Modest Cognitive Improvement
In 1984, researchers first isolated the amyloid protein plaque that has since been identified as the primary sign of Alzheimer’s disease. In the years since that discovery, reducing levels of amyloid has been the goal of scientists seeking effective treatments for this disabling, and ultimately fatal, disease.
George Citroner
Author
George Citroner reports on health and medicine, covering topics that include cancer, infectious diseases, and neurodegenerative conditions. He was awarded the Media Orthopaedic Reporting Excellence (MORE) award in 2020 for a story on osteoporosis risk in men.
